Levodopa Inhalation

Introduction Overview

Generic Name

levodopa inhalation

Brand Name

Inbrija, Dopar, Larodopa

Dosage Form

inhalation capsule (42 mg)

Drug Class

Dopaminergic antiparkinsonism agents

Pharmacokinetics

Absorption:
Levodopa administered via inhalation as Inbrija delivers the drug through the pulmonary route directly into the systemic circulation, bypassing gastrointestinal absorption limitations associated with oral administration. This inhalation route provides rapid uptake with peak plasma concentrations occurring quickly, often within minutes after inhalation. The pulmonary route avoids delays due to gastric emptying variations, first-pass hepatic metabolism, and food interactions typical of oral levodopa administration. The inhalation capsules contain 42 mg of levodopa powder intended to be delivered in small bursts into the lungs via a specialized inhaler device.

Distribution:
Once absorbed systemically via the lungs, levodopa is distributed widely throughout the body. It crosses the blood-brain barrier efficiently as it is the precursor to dopamine, which itself cannot cross into the central nervous system. The volume of distribution correlates with body weight and cerebral blood flow, with levodopa preferentially entering dopaminergic neurons in the basal ganglia regions responsible for motor control. Protein binding is low, allowing rapid tissue availability. Distribution kinetics also explain the relatively short half-life and the necessity for repeated dosing during OFF episodes in Parkinson’s disease.

Metabolism:
Levodopa undergoes extensive peripheral metabolism primarily by aromatic L-amino acid decarboxylase (DOPA decarboxylase) to dopamine, as well as by catechol-O-methyltransferase (COMT) and monoamine oxidases (MAO). This metabolism occurs in various tissues including the liver, kidney, and vascular endothelium before the drug reaches the brain. Co-administration with carbidopa, a peripheral decarboxylase inhibitor, is essential to prevent peripheral conversion and to increase central availability of levodopa. Inhalation bypasses first-pass hepatic metabolism but peripheral enzymatic degradation remains an important factor affecting bioavailability.

Elimination:
The primary elimination pathway for levodopa and its metabolites is renal excretion. Approximately 90% of administered levodopa is eliminated via urine predominantly as metabolites including 3-O-methyl-dopa and homovanillic acid. The elimination half-life after oral levodopa is approximately 1-2 hours; inhaled levodopa demonstrates a similar kinetic profile though onset is faster. Renal function and concurrent medications affecting enzymes involved in levodopa metabolism can alter elimination rates, affecting efficacy and side effect profiles. Clinical implications include dose adjustments in renal impairment and monitoring for accumulation or toxicity.

Dosage Forms

Available Dosage Forms:
Levodopa inhalation is exclusively available as a dry powder contained in inhalation capsules, each containing 42 mg of levodopa. These capsules are designed for use solely with the Inbrija inhaler device, which pierces the capsule to release the powder into the device for pulmonary delivery.

Dosages for Adults and Adolescents:
The recommended dosing regimen for treating 'OFF episodes' in Parkinson’s disease involves inhalation of 84 mg (two 42 mg capsules) as needed when symptoms of an OFF episode start to return. The maximum permitted dosing is five times per day, totaling a maximum daily dose of 420 mg. The capsules should not be swallowed but inhaled fully using the inhaler device for optimal bioavailability.

Specific Patient Populations:
Levodopa inhalation is approved for use in adult patients currently taking carbidopa/levodopa therapy but experiencing intermittent OFF episodes. Usage in pediatric populations, pregnant or breastfeeding women requires caution due to limited safety data. Patients with respiratory disorders such as asthma or COPD are advised to use this medication cautiously, given its inhalation route and potential for bronchospasm or other pulmonary side effects. Renal or hepatic impairment may require close monitoring but no specific dose adjustments are universally recommended. Elderly patients may demonstrate increased sensitivity to dopamine agonists and hence should be monitored closely for adverse effects.

Mechanism Of Action

Levodopa is a metabolic precursor of dopamine, a critical neurotransmitter involved in modulating motor function through the basal ganglia circuitry. After inhalation and systemic absorption, levodopa crosses the blood-brain barrier via large neutral amino acid transporters. In the brain, it is enzymatically decarboxylated to dopamine by aromatic L-amino acid decarboxylase within dopaminergic neurons primarily located in the substantia nigra and striatum. This replenishment restores dopaminergic neurotransmission depleted in Parkinson's disease due to degeneration of dopaminergic neurons.

The increased dopamine availability in the striatum helps normalize the impaired signaling pathways that cause the characteristic motor symptoms of Parkinson’s disease such as bradykinesia, rigidity, and tremor. By restoring dopamine tone, levodopa enhances the direct pathway while inhibiting the indirect pathway within basal ganglia circuits, thus improving motor function.

Levodopa’s clinical efficacy is enhanced when administered with carbidopa, a peripheral decarboxylase inhibitor, which prevents peripheral conversion of levodopa to dopamine reducing systemic side effects such as nausea and cardiovascular symptoms, and ensuring more levodopa reaches the brain.

Compared to other antiparkinsonian agents, such as dopamine agonists (e.g., pramipexole, ropinirole), levodopa provides direct substrate replacement rather than receptor stimulation, resulting in more robust symptom control but also a higher risk of motor fluctuations and dyskinesias with long-term use. Recent studies emphasize the utility of inhaled levodopa formulations for rapid symptom relief during OFF episodes, capitalizing on pulmonary absorption for timely dopamine repletion.

Pharmacological Actions

Acts as a dopamine precursor to increase central nervous system dopamine concentrations.
Crosses the blood-brain barrier via amino acid transport systems.
Restores dopaminergic neurotransmission in Parkinson’s disease.
Improves motor function by modulating basal ganglia pathways.
Rapid onset of action when administered via inhalation due to pulmonary absorption.
Reduces OFF-time duration in Parkinson’s disease patients treated with carbidopa/levodopa.
Used as adjunct therapy to manage intermittent motor symptom fluctuations.
Minimal peripheral dopamine formation when combined with carbidopa.
Indirectly inhibits overactivity of cholinergic pathways involved in motor symptoms.
Does not alter the progression or neurodegeneration of Parkinson’s disease.
May cause central nervous system effects such as hallucinations, confusion, or dyskinesias.
Associated with potential development of impulsive-compulsive behaviors with prolonged use.
Exhibits dose-dependent pharmacological profile requiring careful titration.
Absorbed rapidly through lungs when inhaled, bypassing gastrointestinal variables.
Effective in treating Parkinson’s disease symptoms such as rigidity, bradykinesia, and sometimes tremor.

Therapeutic Or Clinical Uses

Management of motor symptoms in Parkinson’s disease patients.
Treatment of OFF episodes in patients on carbidopa/levodopa therapy.
Rapid alleviation of return of Parkinson’s symptoms during OFF periods.
Adjunct therapy to oral levodopa/carbidopa regimens to improve motor fluctuations.
Improvement of rigidity and bradykinesia symptoms.
Sometimes used for tremor control in Parkinson’s disease.
Symptomatic treatment when oral levodopa dosages are insufficient or impractical.
Beneficial for patients experiencing delayed ON or dose failures with oral medications.
Used in patients with fluctuating response to long-term levodopa therapy.
Not indicated for monotherapy or initial treatment of Parkinson’s disease.
Therapy aimed at improving quality of life by reducing OFF-time duration.
Applicable to patients with motor fluctuations despite optimized oral regimens.
Option for patients with gastrointestinal absorption issues limiting oral levodopa efficacy.
May be used in combination with other dopaminergic antiparkinsonism agents.
Not established for use in pediatric patients or other movement disorders outside Parkinson’s.

Side Or Adverse Effects

Cough and throat irritation due to inhalation delivery.
Cold symptoms including sneezing, stuffy nose, and sore throat.
Nausea commonly observed with dopaminergic therapy.
Dark discoloration of sweat, saliva, or urine.
Sudden onset of sleepiness or falling asleep during activities.
Uncontrolled involuntary muscle movements (dyskinesias), especially facial.
Confusion, hallucinations, paranoia, and other psychotic symptoms.
Excessive urges including gambling, sexual urges, binge eating, or compulsive spending.
Agitation, aggression, and increased dreaming or difficulty sleeping.
Orthostatic hypotension causing dizziness or fainting.
Potential for allergic reactions including hives, facial swelling, and breathing difficulty.
Bronchospasm or chest tightness post-inhalation, especially in patients with respiratory disease.
Withdrawal symptoms including muscle stiffness and altered breathing if abruptly discontinued.
Gastrointestinal discomfort related to dopaminergic stimulation.
Sleep disturbances including vivid dreams and insomnia.

Precautions

Do not use if recent treatment with monoamine oxidase inhibitors (within 14 days).
Caution in patients with asthma, COPD, or other respiratory disorders due to inhalation route.
Screen for a history of glaucoma before initiation.
Monitor for involuntary muscle movements indicating dyskinesias.
Assess for daytime sleepiness or sleep disorders before and during treatment.
Use cautiously in patients with orthostatic hypotension.
Evaluate mental health status for psychosis, hallucinations, or paranoia symptoms.
Monitor for development of impulse control disorders or compulsive behaviors.
Pregnancy and breastfeeding risks are unclear; use only if benefits justify potential risks.
Do not swallow capsules; intended only for inhalation via the prescribed device.
Avoid abrupt discontinuation to prevent withdrawal syndrome.
Inform patients about potential drowsiness and caution regarding driving or hazardous tasks.
Store capsules separately from inhaler device to maintain drug integrity.
Regularly assess dosage appropriateness considering symptom control and side effects.
Monitor renal function as impaired elimination may require closer observation.

Warnings

Follow the prescribed dosing strictly; do not exceed five doses per day.
May cause sudden sleep episodes during daily activities leading to serious injury.
Avoid concurrent use with MAO inhibitors to prevent hypertensive crisis.
Use with caution in patients with a history of psychosis or severe mental illness.
Patients with respiratory disease may experience bronchospasm or breathing difficulties.
Risk of impulse control disorders including gambling, hypersexuality, and compulsive behaviors.
Abrupt cessation after chronic use may cause severe withdrawal symptoms.
Avoid driving or operating machinery until individual response to the drug is known.
Potential for serious allergic reactions requiring immediate medical attention.
Warn patients about the possibility of hallucinations or confusion during therapy.
Drug interaction with dopamine antagonists and iron supplements can reduce efficacy.
Monitor for signs of orthostatic hypotension, especially in elderly patients.
Use in pregnancy or lactation only when benefits outweigh risks due to insufficient data.
Store the inhaler and capsules properly to maintain effectiveness and safety.
Use with caution when combined with sedative medications that may exacerbate drowsiness.

Contraindication

Use within 14 days of treatment with nonselective monoamine oxidase inhibitors such as isocarboxazid and phenelzine.
Known hypersensitivity or allergy to levodopa, carbidopa, or formulation components.
Patients with narrow-angle glaucoma.
Patients with a history of melanoma or undiagnosed skin lesions due to potential activation.
Concurrent use with dopamine antagonists such as antipsychotics that block dopaminergic receptors.
Severe pulmonary disease poorly controlled or with active bronchospasm for inhalation form.
Pregnancy unless clearly necessary and benefits outweigh risks.
Patients unable to properly use inhaler device or follow administration instructions.
Severe cardiovascular disorders with unstable blood pressure or arrhythmias.
History of malignant melanoma or other cancers predisposing to dopaminergic stimulation risks.
Concomitant use with methylene blue when administered intravenously.
Known intolerance to excipients contained in inhalation capsules.

Drug Interactions

Monoamine oxidase inhibitors (MAOIs) can cause hypertensive crisis if combined.
Iron supplements or multivitamins containing iron may reduce levodopa absorption.
Dopamine antagonists such as antipsychotics decrease therapeutic effects.
Metoclopramide may antagonize levodopa's therapeutic effect by dopamine receptor blockade.
Risperidone and other antipsychotics have potential to reduce levodopa efficacy or worsen symptoms.
Opioids, benzodiazepines, muscle relaxants, and other CNS depressants may worsen drowsiness caused by levodopa inhalation.
Isoniazid may interact with CNS dopaminergic pathways and potentiate side effects.
Tricyclic antidepressants and sympathomimetics can potentiate hypertensive effects.
Concomitant use with other antiparkinsonian drugs requires careful clinical monitoring.
Products containing tyramine or serotonergic agents may interact with dopaminergic pathways.
Multiple drug interactions with CYP enzyme modulators affecting metabolism of levodopa metabolites.
Certain vitamin preparations may influence levodopa pharmacokinetics.
Potential interaction with selective serotonin reuptake inhibitors increasing risk of serotonin syndrome.
Use with caution alongside antihypertensive agents due to additive hypotensive effects.
Enzyme inhibitors such as COMT inhibitors modify levodopa metabolism and may alter dosing requirements.

Preparations Of The Drug

Inhalation capsules containing 42 mg levodopa powder designed for use exclusively with the Inbrija inhaler device.
Capsules packaged in blister packs to maintain drug stability and prevent moisture contamination.
Inhaler device designed to pierce the capsule releasing the powder for pulmonary administration.
Oral preparations of levodopa combined with carbidopa available separately; inhalation form is adjunct therapy.
Formulations intended for rapid relief of OFF episodes, complementing continuous oral therapy.
Storage at room temperature away from heat and moisture; capsules must remain in blister until use.
Single-use inhaler discarded after all capsules in prescription have been used.
No capsules to be swallowed whole; intended for inhalation only to achieve intended effect.
No extended-release inhalation forms currently available; dosing based on immediate pulmonary absorption.
Prescription-only medication requiring education on proper inhaler technique for safety and efficacy.
Other formulations of levodopa (oral tablet, extended release, enteral suspension) available for baseline therapy.
Inhalation capsules are nonsterile and intended for pulmonary delivery as dry powder.
Device and capsules are supplied separately and must be used together to ensure correct dosing.
Packaging includes patient instructions emphasizing correct use and avoidance of swallowing capsules.
Commercially available under brand names Inbrija, Dopar, and Larodopa in different markets.